儿童和青少年起始抗精神病药治疗相比年轻成人具有更高的心血管代谢风险:一项全国性队列研究结果
这项丹麦全国性队列研究纳入2000-2021年6-31岁起始抗精神病药治疗的精神科诊断患者,比较儿童青少年与年轻成人相比匹配未暴露者的心血管代谢不良事件风险。儿童青少年暴露者相比未暴露者的校正超额风险(HR=1.87,95%CI:1.71-2.05)显著高于年轻成人暴露者相比未暴露者(HR=1.46,95%CI:1.40-1.51)(p<0.001);12岁前起始治疗的风险(HR=2.44,95%CI:1.99-2.98)高于12-17岁起始(HR=1.69,95%CI:1.52-1.87)(p=0.012)。
要点
- 儿童青少年起始抗精神病药相比匹配未暴露者的心血管代谢事件校正HR=1.87(95%CI:1.71-2.05),高于年轻成人的HR=1.46(95%CI:1.40-1.51)(p<0.001)。
- 12岁前起始抗精神病药的心血管代谢事件超额风险HR=2.44(95%CI:1.99-2.98),高于12-17岁起始的HR=1.69(95%CI:1.52-1.87)(p=0.012)。
- 起始抗精神病药的年轻成人心血管代谢事件发生率为23.2例/1000人年,高于儿童青少年的14.1例/1000人年。
核心结论
- 18岁前起始抗精神病药治疗与相比年龄和性别匹配但未暴露抗精神病药的精神障碍青少年更高的心血管代谢事件超额风险相关。
- 儿童青少年起始抗精神病药的心血管代谢超额风险显著高于成年早期起始者,且儿童期起始显著高于青少年期起始。
- 作者基于这些发现提供了关于儿童和青少年使用抗精神病药的建议。
研究设计与样本
- 丹麦全国性人群基础队列研究,纳入2000-2021年6-31岁起始抗精神病药且有精神科诊断的个体,随访至暴露后10年内心血管代谢不良事件。
- 总队列335,093人,其中暴露于抗精神病药者36,092人(儿童青少年8,547人,平均随访6.8±3.2年;年轻成人27,545人,平均随访6.5±3.4年),年龄、性别和日历时间匹配的未暴露者299,001人。
- 采用Cox回归模型,经高维倾向评分校正年龄、性别、日历时间、医院诊断和处方药使用后计算风险比(HR)。
主要发现
- 起始抗精神病药的年轻成人心血管代谢事件发生率为23.2例/1000人年,高于儿童青少年的14.1例/1000人年。
- 暴露相比未暴露儿童青少年的心血管代谢事件校正HR=1.87(95%CI:1.71-2.05),高于暴露相比未暴露年轻成人的HR=1.46(95%CI:1.40-1.51)(p<0.001)。
- 12岁前起始抗精神病药的心血管代谢事件HR=2.44(95%CI:1.99-2.98),高于12-17岁起始的HR=1.69(95%CI:1.52-1.87)(p=0.012)。
- 起始抗精神病药年龄对代谢综合征风险(p=0.011)和肥胖风险(p<0.001)有影响,儿童青少年中高于年轻成人。
临床怎么用
- 作者基于这些发现提供了关于儿童和青少年使用抗精神病药的建议(原文未列出具体建议条款)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antipsychotic treatment is associated with cardiometabolic risks that may be especially detrimental to children and adolescents. In this Danish population-based cohort study, we included individuals with psychiatric diagnoses who initiated antipsychotics in 2000-2021 at age 6-31 years. We assessed the risk of cardiometabolic adverse events up to 10 years following incident exposure to antipsychotics, compared to age- and sex-matched unexposed individuals with psychiatric diagnoses. Cox regression models were used to calculate hazard ratios (HRs) after adjustment using high-dimensional propensity scores, including age, sex, calendar time, hospital diagnoses, and prescription drug use. HRs were compared between incident exposure in youths (6-17 years) and young adults (18-31 years), and between incident exposure in children (6-11 years) and adolescents (12-17 years). The total cohort consisted of 335,093 individuals, including 36,092 subjects exposed to antipsychotics (children and adolescents: 8,547, mean follow-up: 6.8±3.2 years; young adults: 27,545, mean follow-up: 6.5±3.4 years) and 299,001 age-, sex- and calendar-matched unexposed subjects. The incidence rate of cardiometabolic events was higher for young adults initiating antipsychotics than for children and adolescents (23.2 vs. 14.1 events/1,000 person-years). However, the adjusted excess risk of cardiometabolic events was significantly higher in exposed compared to unexposed children and adolescents (HR=1.87, 95% CI: 1.71-2.05) than in exposed compared to unexposed young adults (HR=1.46, 95% CI: 1.40-1.51) (p<0.001). The excess risk of cardiometabolic events was even higher when antipsychotic treatment was initiated before age 12 years (HR=2.44; 95% CI: 1.99-2.98) than at age 12-17 years (HR=1.69, 95% CI: 1.52-1.87) (p=0.012). Concerning specific cardiometabolic outcomes, there was an effect of age at antipsychotic initiation on the risks of metabolic syndrome (p=0.011) and obesity (p<0.001), that were higher among children and adolescents than young adults. Thus, initiation of antipsychotic treatment before age 18 years is associated with an excess risk of cardiometabolic events compared to age- and sex-matched youths with psychiatric disorders but unexposed to antipsychotics. The excess cardiometabolic risk is significantly higher than that of individuals who start antipsychotic treatment in early adulthood, and significantly higher for treatment onset in childhood compared to adolescence. On the basis of these findings, recommendations are provided about the use of antipsychotics in children and adolescents.
引用
- Højlund M, Wesselhoeft R, Heinrichsen M, et al. Excess cardiometabolic risk in children and adolescents initiating antipsychotic treatment compared to young adults: results from a nationwide cohort study. World Psychiatry. 2025. PMID: 39810688. doi:10.1002/wps.21279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。